Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Cash, Cash Equivalents, Marketable Securities : HK$407 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Cash, Cash Equivalents, Marketable Securities?

Biocytogen Pharmaceuticals (Beijing) Co's quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 (HK$446.36 Mil) to Jun. 2024 (HK$421.91 Mil) but then stayed the same from Jun. 2024 (HK$421.91 Mil) to Dec. 2024 (HK$406.98 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (HK$682.61 Mil) to Dec. 2023 (HK$446.36 Mil) and declined from Dec. 2023 (HK$446.36 Mil) to Dec. 2024 (HK$406.98 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Cash, Cash Equivalents, Marketable Securities Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

1,063.68

693.59

682.61

446.36

406.98

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial				682.61	594.29	446.36	421.91	406.98

Biocytogen Pharmaceuticals (Beijing) Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Biocytogen Pharmaceuticals (Beijing) Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Shen Yuelei
Ni Jian
Zhao Shang Yin Xing Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you
Astral Eminent Limited	2101 Beneficial owner
Wei Ke Xiang Gang Jing Mao You Xian Gong Si	2101 Beneficial owner
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines